Brisbane-based vaccine patch company Vaxxas is developing the first room temperature-stable needleless vaccine for one of the world’s most common cold-like diseases, weeks after launching efforts to raise $100 million. On Tuesday, Vaxxas announced it had received a global licence from the United States National Institutes of Health (NIH). The company will now prepare for…

The post Vaxxas granted licence to develop new needle-free vaccine appeared first on InnovationAus.com.

This post was originally published on InnovationAus.com.